Loading...
•
Jun 30, 2023
Atara Q2 2023 Earnings Report
Reported financial results for the second quarter 2023 and provided recent business highlights.
Key Takeaways
Atara Biotherapeutics reported a net loss of $71.1 million for the second quarter of 2023. They announced IND clearance for ATA3219. Discussions with the FDA and potential commercial partners for tab-cel in the U.S. are progressing well.
IND clearance received for ATA3219, an allogeneic CAR-T cell product candidate.
Discussions with the FDA and potential commercial partners for tab-cel in the U.S. are progressing well.
Primary analysis of the EMBOLD Phase 2 study in progressive MS, with clinical and biomarker data from more than 90 patients will occur in early November.
Patients in Europe are now receiving treatment with EBVALLO in the commercial setting.
Atara
Atara
Forward Guidance
Atara believes that its cash and investments as of June 30, 2023, will be sufficient to fund the Company’s planned operations into second quarter 2024